RCT-Twin-GAN for Simulating Treatment Effects in Real-World Populations
RCT-Twin-GAN is a novel generative AI framework that creates digital twins of randomized clinical trials. By conditioning trial data on specific patient population characteristics—such as those from electronic health records—it allows researchers to simulate and estimate the generalizability of clinical trial treatment effects across diverse real-world settings.
Overview
RCT-Twin-GAN is a generative artificial intelligence framework designed to address the challenges of generalizability in clinical research. While randomized clinical trials (RCTs) are the gold standard for evidence, their results often lack representativeness for real-world patient populations. This solution bridges that gap by creating digital twins—synthetic, statistically informed datasets—of clinical trials that are re-conditioned to reflect the specific covariate distributions of different populations, such as those found in electronic health records (EHR). By doing so, researchers can better estimate how a treatment effect observed in a controlled trial might translate to broader or more diverse patient groups, enhancing causal inference and supporting more informed clinical decision-making.
Technical specifications
The framework utilizes an advanced Generative Adversarial Network (GAN) architecture, specifically optimized to handle the complexities of clinical data. Key capabilities include:
- Statistically Informed Architecture: Incorporates clinical knowledge into the generative process to maintain rigorous relationships between covariates and outcomes.
- Advanced Conditioning: Capable of simultaneously conditioning on multiple discrete and continuous variables, allowing for precise mapping to target population characteristics.
- Loss Function Optimization: Employs a custom loss function adapted for data distributions to improve performance over traditional tabular conditional GANs.
- Balanced Synthetic Cohorts: Generates datasets that maintain randomized treatment and control arms while achieving high similarity to the target population's covariate profile.
Technology readiness level
The technology is currently at TRL 4-5. The approach has been successfully validated through academic research projects, including the reproduction of disparate treatment effects from major clinical studies like the SPRINT and ACCORD trials, as well...
About Yale
Yale University is a comprehensive private research institution with professional schools anchored in New Haven and a modern West Campus. For industry, Yale connects clinical care and research through its affiliation with a major hospital system, enabling access to patients, data, and regulated environments. Companies engage via co-located laboratories and shared core facilities at West Campus and through a research and technology park embedded in New Haven’s growing biotech cluster, with easy reach to New York and Boston. Research is supported by competitive funding from agencies such as NIH, NSF, and DOE. A dedicated technology transfer office (Yale Ventures) partners on IP, licensing, sponsored research, and venture creation.
delivered to your inbox.